Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells

T. Kimura, L. Wang, K. Tabu, M. Tsuda, M. Tanino, A. Maekawa, Hiroshi Nishihara, H. Hiraga, T. Taga, Y. Oda, S. Tanaka

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-Associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.

Original languageEnglish
Pages (from-to)3932-3943
Number of pages12
JournalOncogene
Volume35
Issue number30
DOIs
Publication statusPublished - 2016 Jul 28
Externally publishedYes

Fingerprint

Synovial Sarcoma
Neoplastic Stem Cells
Cell Line
Therapeutics
Microarray Analysis
Heterografts
Sarcoma
Stem Cells
Survival Rate
Biomarkers
Cell Proliferation
Radiation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Kimura, T., Wang, L., Tabu, K., Tsuda, M., Tanino, M., Maekawa, A., ... Tanaka, S. (2016). Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene, 35(30), 3932-3943. https://doi.org/10.1038/onc.2015.461

Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. / Kimura, T.; Wang, L.; Tabu, K.; Tsuda, M.; Tanino, M.; Maekawa, A.; Nishihara, Hiroshi; Hiraga, H.; Taga, T.; Oda, Y.; Tanaka, S.

In: Oncogene, Vol. 35, No. 30, 28.07.2016, p. 3932-3943.

Research output: Contribution to journalArticle

Kimura, T, Wang, L, Tabu, K, Tsuda, M, Tanino, M, Maekawa, A, Nishihara, H, Hiraga, H, Taga, T, Oda, Y & Tanaka, S 2016, 'Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells', Oncogene, vol. 35, no. 30, pp. 3932-3943. https://doi.org/10.1038/onc.2015.461
Kimura T, Wang L, Tabu K, Tsuda M, Tanino M, Maekawa A et al. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene. 2016 Jul 28;35(30):3932-3943. https://doi.org/10.1038/onc.2015.461
Kimura, T. ; Wang, L. ; Tabu, K. ; Tsuda, M. ; Tanino, M. ; Maekawa, A. ; Nishihara, Hiroshi ; Hiraga, H. ; Taga, T. ; Oda, Y. ; Tanaka, S. / Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. In: Oncogene. 2016 ; Vol. 35, No. 30. pp. 3932-3943.
@article{b32bf3df13154d06988f05381bc7d2dc,
title = "Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells",
abstract = "Synovial sarcoma accounts for almost 10{\%} of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36{\%}. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-Associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.",
author = "T. Kimura and L. Wang and K. Tabu and M. Tsuda and M. Tanino and A. Maekawa and Hiroshi Nishihara and H. Hiraga and T. Taga and Y. Oda and S. Tanaka",
year = "2016",
month = "7",
day = "28",
doi = "10.1038/onc.2015.461",
language = "English",
volume = "35",
pages = "3932--3943",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "30",

}

TY - JOUR

T1 - Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells

AU - Kimura, T.

AU - Wang, L.

AU - Tabu, K.

AU - Tsuda, M.

AU - Tanino, M.

AU - Maekawa, A.

AU - Nishihara, Hiroshi

AU - Hiraga, H.

AU - Taga, T.

AU - Oda, Y.

AU - Tanaka, S.

PY - 2016/7/28

Y1 - 2016/7/28

N2 - Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-Associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.

AB - Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-Associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84949256308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949256308&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.461

DO - 10.1038/onc.2015.461

M3 - Article

C2 - 26640147

AN - SCOPUS:84949256308

VL - 35

SP - 3932

EP - 3943

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 30

ER -